Pranava Ganesh, MD
Cardiovascular Disease · Johnson City, NYNPI 1952798712
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,463, more than ten times the $62 reported in 2019.
Across 223 payments — averaging $26.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$770
- Amgen$564
- Abiomed$546
- Merck$518
- Pfizer$499
- Boehringer Ingelheim$491
- plus $3K from 27 others
What the payments were for
- Food & beverage$5,88399%
- Entertainment$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 19 | $770 |
| Amgen | 28 | $564 |
| Abiomed | 12 | $546 |
| Merck | 24 | $518 |
| Pfizer | 29 | $499 |
| Boehringer Ingelheim | 24 | $491 |
| E.r. Squibb & Sons, L.L.C. | 8 | $446 |
| Heartflow, Inc. | 5 | $408 |
| Novartis | 13 | $228 |
| Chiesi USA, Inc. | 7 | $157 |
| Medtronic | 2 | $132 |
| Amarin Pharma, Inc. | 6 | $129 |
| Johnson & Johnson | 6 | $117 |
| AbbVie | 6 | $111 |
| Bridgebio Pharma, Inc. | 5 | $97 |
| BD | 2 | $97 |
| Alnylam Pharmaceuticals Inc. | 4 | $83 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $68 |
| Kestra Medical Technology Services, Inc. | 2 | $60 |
| Boston Scientific | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Akcea Therapeutics, Inc. | 2 | $47 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Stereotaxis Inc | 1 | $36 |
| Haemonetics Corporation | 1 | $24 |
| Inari Medical, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Abbott | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,920 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Johnson City
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.